parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in early spermatids	0.75
chemistry Open Targets	a small-molecule pocket: rintatolimod, bevasiranib, bevasiranib sodium	0.60
trials ClinicalTrials.gov	1 Parkinson's trial, 0 stopped	1.00
literature PubMed	23 Parkinson's papers of 6,561	0.58
pathways Reactome	13 pathways; mostly vesicle traffic	1.00

No case: the score is under the bar. Receipt 5487

receipt 5497: TLR3 in dopamine neurons, braak

power: full sample +0.13 (p 0.609, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.05 (p 0.847, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.03 (p 0.894, n 18). could be the mix.
skeptic: leave-one-out range +0.03 to +0.27, sign flips 0; without severely affected donors +0.13 (p 0.609, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TLR3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5496: TLR3 in microglia, braak

power: full sample +0.21 (p 0.403, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.17 (p 0.509, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.16 (p 0.526, n 18). could be the mix.
skeptic: leave-one-out range +0.11 to +0.36, sign flips 0; without severely affected donors +0.21 (p 0.403, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TLR3 in microglia.

case closed: nothing better to follow up.

loading the receipts